SBIR/STTR Research Award
AN ULTRASOUND SYSTEM FOR THE TREATMENT OF WARTS
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1988Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Ultrathermics Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
VIRAL WARTS ARE AN AFFLICTION FOR WHICH NEW MODALITIES OF TREATMENT ARE NEEDED, ESPECIALLY FOR LARGE, FLAT, RESISTANT AND/OR CLUSTERED LESIONS. PATIENTS AND PHYSICIANS ALIKE AREFRUSTRATED BECAUSE NONE OF THE EXISTING THERAPIES IS COMPLETELY SATISFACTORY. PRELIMINARY CLINICAL STUDIES INDICATE THAT WARTS, LIKE CANCER TUMORS, MAY BE CLEARED AS ARESULT OF BEING HEATED TO TEMPERATURES IN THE HYPERTHERMIC RANGE (42-47 DEGREES (C)). PROPOSED IS THE DEVELOPMENT OF ARELATIVELY SIMPLE AND INEXPENSIVE HYPERTHERMIA SYSTEM CAPABLE OF TREATING WARTS AND OTHER HEAT-SENSITIVE SKIN DISEASES. THE DEVICE, A PORTABLE, SELF-CONTAINED, MICROPROCESSOR-CONTROLLED SYSTEM WELL SUITED FOR USE IN AN OFFICE PRACTICE, WILL BE CAPABLE OF PRODUCING TAILORED THERMAL DISTRIBUTIONS IN SKIN TISSUES BY DYNAMICALLY CONTROLLING THE ACOUSTIC FREQUENCY AND POWER OUTPUT OF AN ULTRASOUND TRANSDUCER, AND THE TEMPERATURE OF THE WATER BOLUS THAT COUPLES THE ENERGY TO THE BODY. PHASE I OF THIS PROJECT SEEKS TO DEMONSTRATE THE FEASIBILITYOF THIS CONCEPT BY FABRICATING SEVERAL CLINICALLY USEFUL APPLICATORS AND TESTING THEIR PERFORMANCE BOTH IN THE LABORATORY AND CLINIC. KEY TO THE SUCCESS OF THIS PHASE IS THE DEVELOPMENT OF A TRANSDUCER CAPABLE OF EFFICIENTLY AND UNIFORMLY RADIATING ULTRASOUND OVER THE FREQUENCY RANGE FROM5 TO 10 MHZ, AND THE SUCCESSFUL COMPLETION OF PILOT CLINICAL STUDIES DEMONSTRATING SAFETY AND EFFICACY FOR CLEARING HUMAN WARTS. BASED ON PHASE I RESULTS, PHASE II WILL REQUEST FUNDING TO DEVELOP THE DEDICATED ELECTRONICS PACKAGE AND FLUID CONDITIONING HARDWARE NECESSARY TO PRODUCE A PROTOTYPE DEVICE AND TO CONDUCT FULL SCALE CLINICAL TRIALS. FROM THESE INVESTIGATIONS, IT IS ANTICIPATED THAT OPTIMIZED TREATMENT PROTOCOLS WILL EMERGE THAT CONFIRM THE POTENCY OF THIS NEW THERAPY, AND THEREBY CREATE DEMAND FOR COMMERCIAL SYSTEMS.
Technology keywords
Not reported